Outwitting immunity to treat disease: Start-up raises 33 millions CHF

May 5, 2014 by Lionel Pousaz, Ecole Polytechnique Federale de Lausanne
Outwitting immunity to treat disease: start-up raises 33 millions CHF
Human T-Cell. Credit: Creative commons NIAID/NIH

EPFL start-up Anokion has the immune system in its sights. The company has developed technology for retraining white blood cells that holds promise for treating autoimmune, allergic, and a number of other diseases. A group of private investors have pledged 33 millions Swiss francs (37 million dollars) into the young company.

What do , type I diabetes and food allergies have in common? All these conditions are caused by an abnormal immune response; that attack their own body cells or overreact to external elements. In EPFL's Innovation Park, the start-up company Anokion is developing an extremely promising technology to treat autoimmune conditions and other maladies. The first are planned for 2017.

And the range of applications isn't just limited to autoimmune disease. The body also develops to many used to treat hemophilia and cancer, for example, and Anokion's approach may be able to prevent these reactions as well. Now, a group of venture capitalists specializing in pharmaceuticals (Novartis Venture Fund, Novo Ventures and Versant Ventures) has recognized the potential and injected 33 millions Swiss francs (37 millions dollars) into the young company.

How to trick the immune system

Anokion's technology takes advantage of a behavior exhibited by white that is still not very well understood. These cells, the advance guard of the , tend to calm down in the presence of cells that are dying normally at the end of their life cycle. Their cousins, the , do just that in healthy individuals, turning over en masse on the order of 200 million per day.

The researchers developed a technique to attach the protein responsible for triggering the immune response onto these red blood cells. A bit like Pavlov's dogs, who learned to associate the sound of a bell with the appearance of food, the white blood cells associate the "foreign" protein with the millions of calming messages released every day by the red blood cells as they expire. The undesirable immune response disappears. In 2012, the EPFL laboratory led by Jeffrey Hubbell used this technique to prevent disease in mice that were developing type I diabetes. The research was published in PNAS and received an enormous amount of attention.

"The technology delivers proteins, be they autoimmune antigens or protein drugs, in a manner that re-trains the immune system to accept them as the body's own," explains Hubbell "We are delighted that leading biotech venture funds have recognized the value of our approach, providing the necessary financial means to move forward."

Anokion's mission is to commercialize this discovery so that it can move out of the lab and into use as a treatment for disease. For now, the researchers are concentrating on a specific kind of white blood cell, T lymphocytes, that are implicated in many autoimmune and allergic diseases, including multiple sclerosis and type I diabetes.

The technology has a far wider potential, however. Protein drugs are used to treat diseases such as cancer and a number of genetic diseases such as hemophilia. Despite their effectiveness in treating these diseases, the body frequently recognizes these proteins as foreign and mounts an immune response against them, sometimes even after one or a few doses. After this, the body neutralizes the protein drugs that have been developed to heal it.

Using Anokion's technique, the drug could be administered over a much longer period by teaching the immune system to leave it alone. Multiple therapeutic molecules that trigger immune reactions have been withdrawn after clinical trials due to these immunogenicity challenges. The researchers think that many of these could be rehabilitated if the of the T-cells during treatment could be controlled.

Anokion is planning clinical trials for 2017. They will initially test their technology in conjunction with a drug known to trigger strong immune reactions before moving on to autoimmune diseases.

Explore further: Autoimmune disease—retraining white blood cells

Related Stories

Autoimmune disease—retraining white blood cells

December 17, 2012
Symptoms of an autoimmune disease disappeared after a team of scientists retrained the white blood cells. This method is extremely promising for treating diseases such as type I diabetes and multiple sclerosis.

Sensitive balance in the immune system

April 11, 2014
Apoptosis is used by cells that are changed by disease or are simply not needed any longer to eliminate themselves before they become a hazard to the body—on a cellular level, death is part of life. Disruption of this process ...

OSU finds new compound that could treat autoimmune diseases

March 21, 2014
(Medical Xpress)—Scientists at Oregon State University have discovered a chemical compound that could be a safer alternative for treating autoimmune diseases.

Genome study identifies three possible drug candidates for autoimmune diseases

May 2, 2014
(Medical Xpress)—New pharmaceuticals to fight autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and psoriasis, may be identified more effectively by adding genome analysis to standard drug screening, ...

Immune protein could stop diabetes in its tracks

May 20, 2013
Melbourne researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed.

Explainer: What is the immune system?

January 8, 2014
The immune system is an integral part of our body, keeping us safe from diseases – from the common cold to more severe illnesses such as cancer.

Recommended for you

Improving vaccines for the elderly by blocking inflammation

January 22, 2018
By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.